First patient included in Chordate Medical’s pilot study PM009

Chordate Medical Holding AB (publ) (“Chordate”) announced today that the first patient has been included in the company’s open pilot study PM009. The study aims to evaluate the effectiveness of Ozilia in the preventive treatment of patients with chronic migraine who do not respond to treatment with CGRP inhibitors and other migraine medications.

“PM009 is an important study with significant potential upside for the company. Every level of positive results from the study could represent a great opportunity for the company, as the patient group in question has very few treatment options left”, says Anders Weilandt, Chordate CEO.

PM009 is being conducted at King’s College in London with three to four referring clinics and Dr. Jan Hoffmann as the responsible principal investigator. The goal is to include 25–30 patients in the study.

“PM009 is a pilot study where we can learn more about how Ozilia can help people with chronic migraine who have no other options left. The patients participating in the study have already tried at least three other preventive medications before being treated with CGRP inhibitors, and when they also do not respond to CGRP, there are not many more possibilities. Hopefully, Ozilia can have a positive effect for some of them”, says Jan Hermansson, Chordate CSO.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia®, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy